Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Black Diamond Therapeutics, Inc. (BDTX : NSDQ)

• Company Description    Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor and tyrosine-protein kinase. Black Diamond Therapeutics Inc. is based in Cambridge, Massachusetts. Number of Employees: 24

• Price / Volume Information    Yesterday's Closing Price: $3.25 Daily Weekly Monthly 20 Day Moving Average: 753,983 shares Shares Outstanding: 56.94 (millions) Market Capitalization: $185.04 (millions) Beta: 2.93 52 Week High: $6.23 52 Week Low: $1.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.49% 14.44% 12 Week 39.48% 26.70% Year To Date 51.87% 40.60%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE MAIN STREET 14TH FLOOR - CAMBRIDGE,MA 02142 USA ph: 617-252-0848 fax: - investors@bdtx.com None

• General Corporate Information    Officers Mark A. Velleca - President; Chief Executive Officer; Chairman and D Erika Jones - Senior Vice President; Finance Ali Behbahani - Director Samarth Kulkarni - Director Shannon Campbell - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09203E105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 56.94 Most Recent Split Date: (:1) Beta: 2.93 Market Capitalization: $185.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.33 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: 9.73 Trailing 12 Months: 14.13 PEG Ratio: - Price Ratios Price/Book: 1.39 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 47.22% vs. Previous Quarter: -119.39% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - 12.70 03/31/25 - 4.70 12/31/24 - -70.37 ROA 06/30/25 - 9.58 03/31/25 - 3.47 12/31/24 - -50.40 Current Ratio 06/30/25 - 8.73 03/31/25 - 9.24 12/31/24 - 4.92 Quick Ratio 06/30/25 - 8.73 03/31/25 - 9.24 12/31/24 - 4.92 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - 20.63 03/31/25 - 7.27 12/31/24 - - Book Value 06/30/25 - 2.33 03/31/25 - 2.50 12/31/24 - 1.47 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©